Baricitinib (Olumiant; Eli Lilly), an oral Janus kinase (JAK) 1/2 inhibitor, led to significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks in adolescents with severe alopecia areata, ...

Explore the latest advances in alopecia areata treatment, including FDA-approved JAK inhibitors and promising topical ...

Long term data were announced from a phase 3 trial evaluating baricitinib in adolescents aged 12 to less than 18 years with severe alopecia areata.

The alopecia areata market is projected to grow significantly in the seven major markets, driven by an expanding pipeline with diverse mechanisms of action, including JAK inhibitors and IL-2 T ...

The company’s total revenue from operations in Q2FY26 increased nearly 9% to ₹14,478.31 crore from ₹13,291.39 crore, ...

Aquestive Therapeutics ( ($AQST) ) has shared an announcement. Aquestive Therapeutics reported its third quarter 2025 financial results and ...

Sun Pharma's Q2FY26 net profit rose 2.5% to Rs 3,118 crore on 8.9% revenue growth led by India and emerging markets, even as ...

Sun Pharmaceutical Industries officially announced here on Wednesday that it has reported a consolidated net profit of Rs 3,117.95 crore in the second quarter of FY26, registering a growth of 2.55pc ...

Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the ...

The discussion will focus on the Company’s product candidate Anaphylm™ (dibutepinephrine) Sublingual Film, including regulatory progress and commercial readiness. Aquestive management team ...

Autoimmune diseases are on the rise in the U.S., with as many as 50 million Americans affected. Learn what causes them—and which symptoms could help pinpoint your problem.

Starting with immunology, we announced positive top line results from the second Phase III Rinvoq alopecia areata trial, reinforcing the potential for Rinvoq to significantly improve hair regrowth for ...